AstraZeneca and Bristol Myers Squibb in Talks on Possible $400 Billion Merger

AstraZeneca, the UK's biggest drugmaker, has been in talks to combine with U.S. rival Bristol Myers Squibb, according to a Financial Times report published Sunday, August 2, 2026, citing people familiar with the matter. The combined company would be worth close to $400 billion, per the FT. That would make it one of the largest pharmaceutical mergers in history. According to Reuters, the talks have been going on for months. The wire service reported that a deal could come together soon, or it could stall out, or it could fall apart entirely. Nobody's signing anything today. AstraZeneca declined to comment. Bristol Myers Squibb did not respond to a request for comment outside regular business hours, according to Reuters.

Why This Isn't Confirmed

Yet This is still a rumored deal, not an announced one. No merger agreement has been signed. No regulatory filing has been made public. No board vote has been disclosed. Companies talk to each other about mergers constantly and most of those conversations go nowhere. The FT's own sourcing, described only as "people familiar with the matter," leaves plenty of room for this to evaporate, get renegotiated, or turn into something smaller than a full merger. CNBC's coverage flagged this directly, framing its own report as a "developing story" and noting it's "still unclear whether the deal will come together." That's the honest way to handle a rumor sourced to unnamed people: say what's known, say what isn't, and don't pretend a leak is a signed contract.

The Numbers Behind the Interest There's a

real business logic here. According to Reuters, AstraZeneca's cancer treatments pulled in about $25 billion in 2025 sales, roughly half the company's total revenue. Cardiovascular, renal, and metabolism treatments added another $12 billion. The company posted strong second-quarter results just last week on continued demand for cancer and rare-disease drugs, Reuters reported. Reuters also noted that AstraZeneca's share price has more than quadrupled during CEO Pascal Soriot's 14-year tenure, outpacing both the broader FTSE 100 index and its main British rival, GSK. Last year, AstraZeneca announced plans for a direct U.S. stock listing, aiming to tap into higher valuations in American markets while keeping its London listing. That U.S.-listing move is significant context. A company that's already positioning itself to be judged more like an American pharma giant, and less like a British one, is a company that might be more open to an American merger partner too.

The Pfizer Ghost in the Room

Reuters pointed out that this potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by Pfizer, the larger U.S. drugmaker. That 2014 fight was ugly and public. AstraZeneca's board rejected Pfizer's bid, and the UK government at the time got involved over concerns about jobs and research investment on British soil. If AstraZeneca is now the one at the table discussing a combination with an American company, rather than fighting one off, that's a notable shift in posture over a decade. Whether it's driven by a stronger negotiating position this time, changed market conditions, or something else, the sources don't say.

What To Watch

The Straits Times, syndicating the Reuters wire copy, ran the story essentially unchanged. Everyone's working off the same FT sourcing, and nobody has independently nailed down more detail. Watch for three things. First, any on-record statement from AstraZeneca or Bristol Myers Squibb beyond a "no comment." Second, any regulatory filing in the UK or U.S. that would be required if talks move toward a binding agreement. Third, reaction from UK officials, given the political sensitivity around foreign takeovers of AstraZeneca after the Pfizer episode. None of that has happened yet. As of Sunday, August 2, 2026, this is a reported set of talks, not a deal, and the FT's own framing leaves room for it to go nowhere.